QUOTED. Oct. 17, 2018. Ian Crosbie.
Executive Summary
Significant market adoption of Sequana Medica's pump targeting fluid build-up that is linked to liver cirrhosis will depend on the company's ability to reach beyond patients with alcohol-related liver diseases to those with"non-alchoholic steatohepatitis," or NASH, the firm's CEO explains here.
- Find out more: Sequana Medical Pumped About NASH's Market Potential